The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects

Area of Science:

• Pharmacology
• Neuroscience
• Drug Development

Background:

• Opioid receptors are key targets for pain management.
• Traditional mu-opioid receptor (MOR) agonists provide analgesia but cause significant adverse effects.
• Understanding opioid signaling pathways is crucial for developing safer analgesics.

Purpose of the Study:

• To review the current understanding of opioid pathways in analgesia and adverse effects.
• To highlight oliceridine as a novel MOR agonist with selective signaling.
• To discuss the potential of selective MOR agonists in improving pain management.

Main Methods:

• Literature review of studies on opioid pathways and oliceridine.
• Analysis of signaling mechanisms (G protein vs. β-arrestin).
• Comparison of oliceridine's effects with traditional MOR agonists.

Main Results:

• Oliceridine selectively activates G protein and β-arrestin signaling pathways.
• Evidence suggests oliceridine may offer analgesic benefits with reduced adverse effects compared to existing MOR agonists.
• Oliceridine provides the analgesic effects of a pure opioid agonist while potentially limiting adverse effects mediated by the β-arrestin pathway.

Conclusions:

• Selective activation of opioid signaling pathways is a promising strategy for developing safer analgesics.
• Oliceridine represents a novel therapeutic approach for pain management.
• Advances in understanding G protein-coupled receptors are driving the development of new analgesic therapies.